Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic

Respiratory Medicine Case Reports

Michael A. Bellio¹  Aisha Khan²  Gwendolyn Haskell³  Xiumin Xu³  Maria Ines Mitrani⁴  Allen Meglin⁴  Alissa Arango⁴  George C. Shapiro⁴ 

[1] Corresponding author.;Advanced Regenerative Therapies, Savanah, GA, USA;AssureImmune LLC., Miami, FL, USA;Organicell Regenerative Medicine, Inc., Miami, FL, USA;

关键词: COVID-19;    Extracellular vesicles;    Perinatal;    Long-hauler;    Long COVID;   

DOI  :  

来源: DOAJ

【 摘 要 】

Post-COVID-19 infection symptoms such as mental fog, tachycardia, and extreme fatigue are just a few of the symptoms wreaking havoc on patients’ lives. Patients with long-term symptoms following COVID-19 are being called long haulers. To date, long haulers are receiving little to no guidance from physicians on their lingering COVID-19 symptoms with limited treatment options available. Zofin is an acellular biologic that contains the extracellular vesicle (EV) fraction of human amniotic fluid and is under investigation for use as a COVID-19 therapeutic. We obtained FDA and IRB approval to investigate the therapeutic use of Zofin in a single long hauler patient case experiencing prolonged shortness of breath and respiratory impairment. Administration of the EV product was shown to be safe. Furthermore, demonstrated respiratory improvements through chest X ray images and oxygen saturation measurement. The single patient IND studies were completed without any reported adverse events or safety concerns. Furthermore, these completed studies demonstrate the feasibility and a therapeutic potential of amniotic fluid-derived EVs for COVID-19 long hauler intervention.

【 授权许可】

Unknown